Twist Bioscience Shares Rise 8.6% Despite Mixed Analyst Views
Twist Bioscience shares gained 8.6% in midday trading to $165.19, with volume about 70% below average. Analysts are divided, resulting in a Hold consensus and an average price target of $128.17. The company beat quarterly revenue expectations with $118.38 million, up 23.2% year over year, but missed earnings with a $0.56 per-share loss; insiders have sold roughly $93.4 million in shares over three months.
Twist Bioscience, a Nasdaq-listed company, saw its stock climb 8.6% by midday Friday, reaching $165.19 after closing at $152.05. Trading volume was unusually light: 512,240 shares changed hands, roughly 70% below the average daily volume of 1,687,368.
The company recently reported quarterly revenue of $118.38 million, exceeding estimates of $114.55 million and rising 23.2% from a year earlier. However, it posted a per-share loss of $0.56, missing the expected $0.51 loss. Analysts remain split, with eight Buy ratings, three Hold ratings, and two Sell ratings, yielding a Hold consensus and a $128.17 average target.
Count: first para 38? Let's count. "Twist Bioscience, a Nasdaq-listed company, saw its stock climb 8.6% by midday Friday, reaching $165.19 after closing at $152.05. Trading volume was unusually light: 512,240 shares changed hands, roughly 70% below the average daily volume of 1,687,368." Words: Twist1 Bioscience2 a3 Nasdaq-listed4 company5 saw6 its7 stock8 climb9 8.6%10 by11 midday12 Friday13 reaching14 $165.1915 after16 closing17 at18 $152.0519 Trading20 volume21 was22 unusually23 light24 512,24025 shares26 changed27 hands28 roughly29 70%30 below31 the32 average33 daily34 volume35 of36 1,687,36837. Good.
Second: "The company recently reported quarterly revenue of $118.38 million, exceeding estimates of $114.55 million and rising 23.2% from a year earlier. However, it posted a per-share loss of $0.56, missing the expected $0.51 loss. Analysts remain split, with ei
1 paragraph under 90 words measured analysis possible impact on society — who affected and how, framed as reasoned perspective ("could", "may"), never as fact, no political advocacy. Need mention investors, employees, biotech sector? Stock moves may affect shareholders, employees with equity comp, customers/suppliers? Twist Bioscience is synthetic biology/DNA? Material doesn't explicitly say what company does. We can say "The share move and mixed analyst views could affect investors, employees with equity compensation, and the broader biotech financing environment." But "biotech" maybe from company name? Twist Bioscience, bioscience. Material doesn't explicitly say biotech but name. Could say "life-sciences company" maybe. Need no invent specifics. Impact on society: retail/institutional investors may see portfolio shifts; insider sales could influence confidence; revenue growth may support research tools? But don't invent. We can say "For investors, the gap between the market price an